基于iTRAQ蛋白质组学技术对前列腺癌血清标志物的筛查

目的:应用同位素标记相对和绝对定量（iTRAQ）蛋白质组学技术筛选前列腺癌血清中的差异表达蛋白质，提供新的候选标志物。方法:收集4组患者的外周血清标本:良性前列腺增生（BPH）（n=10）、高级别前列腺上皮内瘤变（HGPIN）（n=10）、局限性前列腺癌（localized PCa）（n=10）以及伴有远处转移的前列腺癌（metastatic PCa）（n=10）。每组10例患者的血清样本进行等体积混合后，应用iTRAQ技术联合液相串联质谱分析（LC-ESI-MS/MS）对蛋白质进行鉴定和相对定量。结果:在患者外周血清中共鉴定到蛋白质825个。相对于良性前列腺增生，在前列腺癌组中表达差异在1.2倍以上的蛋白质13个，其中9个表达上调，4个表达下调。结论:基于iTRAQ技术的蛋白质组学方法有助于鉴定出前列腺癌相关的差异蛋白质，为进一步探索前列腺癌肿瘤标志物提供了新的思路和线索。

Screening study for prostate cancer serum biomarkers based on iTRAQ proteomic technology

Objective:To screen the differentially expressed serum proteins in patients with prostate cancer (PCa) and benign prostatic disease using isobaric tag for relative and absolute quantitation (iTRAQ) technology.Methods:Serum samples were collected from 4 groups of patients:benign prostatic hyperplasia (BPH) (n=10)，high grade prostatic intraepithelial neoplasia (HGPIN) (n=10)，localized PCa (n=10) and metastatic PCa (n=10).Equal volumes of serum from 10 patients within the same group were mixed.Then iTRAQ proteomic approach was used to identify and quantify the proteins differentially expressed in these groups.Results:A total of 825 serum proteins were finally identified，among which 13 showed at least 1.2 fold differences between the BPH and PCa group.Nine proteins were up-regulated and 4 proteins were down-regulated.Conclusion:A number of novel proteins associated with PCa could be identified based on iTRAQ proteomic approach，which provided new clues for the discovery of PCa biomarkers.